Medizinische Universität Graz - Research portal
Navigation/Search
- Researchers
- Institutions
- Projects
- Publications
- Partners
- Sponsors
- Equipment
- Knowhow
- Fields of Research
"Faces" of the day:
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Giacobbe, DR; Prattes, J; Wauters, J; Dettori, S; Signori, A; Salmanton-García, J; Maertens, J; Bourgeois, M; Reynders, M; Rutsaert, L; Van, Regenmortel, N; Lormans, P; Feys, S; Klimko, N; Shadrivova, O; Cornely, OA; Rautemaa-Richardson, R; Koehler, P; Lagrou, K; Bassetti, M; Hoenigl, M, , ECMM-CAPA, Study, Group.
Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study.
J Clin Microbiol. 2022; 60(4):e0229821
Doi: 10.1128/jcm.02298-21
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Prattes Jürgen
- Co-authors Med Uni Graz
- Hönigl Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Critically ill patients with coronavirus disease 2019 (COVID-19) may develop COVID-19-associated pulmonary aspergillosis (CAPA), which impacts their chances of survival. Whether positive bronchoalveolar lavage fluid (BALF) mycological tests can be used as a survival proxy remains unknown. We conducted a post hoc analysis of a previous multicenter, multinational observational study with the aim of assessing the differential prognostic impact of BALF mycological tests, namely, positive (optical density index of ≥1.0) BALF galactomannan (GM) and positive BALF Aspergillus culture alone or in combination for critically ill patients with COVID-19. Of the 592 critically ill patients with COVID-19 enrolled in the main study, 218 were included in this post hoc analysis, as they had both test results available. CAPA was diagnosed in 56/218 patients (26%). Most cases were probable CAPA (51/56 [91%]) and fewer were proven CAPA (5/56 [9%]). In the final multivariable model adjusted for between-center heterogeneity, an independent association with 90-day mortality was observed for the combination of positive BALF GM and positive BALF Aspergillus culture in comparison with both tests negative (hazard ratio, 2.53; 95% CI confidence interval [CI], 1.28 to 5.02; P = 0.008). The other independent predictors of 90-day mortality were increasing age and active malignant disease. In conclusion, the combination of positive BALF GM and positive BALF Aspergillus culture was associated with increased 90-day mortality in critically ill patients with COVID-19. Additional study is needed to explore the possible prognostic value of other BALF markers.
- Find related publications in this database (using NLM MeSH Indexing)
- Aspergillus - administration & dosage
- Bronchoalveolar Lavage Fluid - administration & dosage
- COVID-19 - complications
- Critical Illness - administration & dosage
- Galactose - analogs & derivatives
- Humans - administration & dosage
- Intensive Care Units - administration & dosage
- Invasive Pulmonary Aspergillosis - complications, diagnosis
- Mannans - administration & dosage
- Mycology - administration & dosage
- Prognosis - administration & dosage
- Pulmonary Aspergillosis - administration & dosage
- Sensitivity and Specificity - administration & dosage
- Find related publications in this database (Keywords)
- CAPA
- GM
- biomarker
- galactomannan
- Aspergillus
- COVID-19
- BALF